Komori Manabu, Morita Yuka, Tono Tetsuya, Matsuda Keiji, Yamamoto Yutaka, Sakagami Masafumi, Hato Naohito, Kojima Hiromi, Takahashi Haruo
Department of Otolaryngology, St. Marianna University School of Medicine, Japan.
Department of Otolaryngology, Niigata University, Japan.
Auris Nasus Larynx. 2021 Aug;48(4):555-564. doi: 10.1016/j.anl.2020.09.011. Epub 2020 Sep 25.
This study was aimed to determine the characteristics of middle ear cholesteatoma and to investigate short-term outcomes regarding the rates of residual and recurrent cholesteatoma and the postoperative hearing results in Japan, via a nationwide survey using staging and classification criteria for middle ear cholesteatoma, as proposed by the Japan Otological Society (JOS).
The first-round survey was conducted in 2016. The target was patients with middle ear cholesteatoma who were surgically treated in Japan between January and December 2015. Medical information on the patients was anonymized. The questionnaire entries were age, sex, cholesteatoma classification and stage, preoperative hearing level, mastoid development, status of the stapes, and surgical method. There were a total of 1,787 registered patients from 74 facilities from all over Japan. The second survey was conducted in January 2018 and received 1,456 responses from 49 facilities in Japan. Of the 1,456 cases, 1,060 were conducted in the postoperative hearing survey and 1,084 in the residual recurrence survey.
The most common cholesteatoma type was pars flaccida cholesteatoma (63.3%), followed by pars tensa cholesteatoma (13.0%), congenital cholesteatoma (12.9%), and cholesteatoma secondary to chronic tensa perforation (5.6%). Cholesteatoma of uncertain origin accounted for 5.0% (90 cases). Stage II was predominant in pars flaccida and pars tensa cholesteatoma, which frequently involves the mastoid, whereas about half of cases of cholesteatoma secondary to chronic tensa perforation and congenital cholesteatoma were classified as stage I. One hundred fifty-two of 1,084 cases (14.0%) had recurrent cholesteatoma, residual cholesteatoma, or both following first surgeries. The postoperative rates of hearing success rate was 63.3%.
We were able to clarify not only the current epidemiological status of middle ear cholesteatoma but also the current trends of cholesteatoma surgery in Japan. The development of a staging system by the JOS Committee serving an epidemiological database for international or time-dependent comparison. It is possible to use this staging system with reasonable reliability.
本研究旨在通过一项全国性调查,采用日本耳科学会(JOS)提出的中耳胆脂瘤分期和分类标准,确定中耳胆脂瘤的特征,并调查日本残余和复发性胆脂瘤发生率及术后听力结果的短期情况。
第一轮调查于2016年进行。目标是2015年1月至12月在日本接受手术治疗的中耳胆脂瘤患者。患者的医疗信息进行了匿名处理。调查问卷条目包括年龄、性别、胆脂瘤分类和分期、术前听力水平、乳突发育情况、镫骨状况以及手术方法。共有来自日本各地74家机构的1787名注册患者。第二次调查于2018年1月进行,收到了来自日本49家机构的1456份回复。在这1456例病例中,1060例进行了术后听力调查,1084例进行了残余复发调查。
最常见的胆脂瘤类型是松弛部胆脂瘤(63.3%),其次是紧张部胆脂瘤(13.0%)、先天性胆脂瘤(12.9%)以及继发于慢性紧张部穿孔的胆脂瘤(5.6%)。起源不明的胆脂瘤占5.0%(90例)。II期在松弛部和紧张部胆脂瘤中占主导地位,这两种类型常累及乳突,而继发于慢性紧张部穿孔的胆脂瘤和先天性胆脂瘤约一半病例被分类为I期。在1084例病例中,有152例(14.0%)在首次手术后出现复发性胆脂瘤、残余胆脂瘤或两者皆有。术后听力成功率为63.3%。
我们不仅能够阐明中耳胆脂瘤的当前流行病学状况,还能了解日本胆脂瘤手术的当前趋势。JOS委员会开发的分期系统为国际或时间依赖性比较提供了一个流行病学数据库。使用这个分期系统具有合理的可靠性。